These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 29848327)

  • 1. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damage response and neoantigens: A favorable target for triple-negative breast cancer immunotherapy and vaccine development.
    Subbarayan R; Srinivasan D; Balakrishnan R; Kumar A; Usmani SS; Srivastava N
    Int Rev Cell Mol Biol; 2024; 389():104-152. PubMed ID: 39396845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
    Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
    Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving immunotherapeutic solutions for triple-negative breast carcinoma.
    Wu S; Ge A; Deng X; Liu L; Wang Y
    Cancer Treat Rev; 2024 Nov; 130():102817. PubMed ID: 39154410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
    Sivaganesh V; Promi N; Maher S; Peethambaran B
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in triple-negative breast cancer.
    Katz H; Alsharedi M
    Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects.
    Ahmed RF; Jameel F; Irfan M
    Crit Rev Immunol; 2019; 39(3):211-221. PubMed ID: 32421965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-negative breast cancer-derived exosomes change the immunological features of human monocyte-derived dendritic cells and influence T-cell responses.
    Safaei S; Alipour S; Bahojb Mahdavi SZ; Shalmashi H; Shahgoli VK; Shanehbandi D; Baradaran B; Kazemi T
    Mol Biol Rep; 2024 Oct; 51(1):1058. PubMed ID: 39417912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
    Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
    Front Oncol; 2022; 12():919072. PubMed ID: 35795050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
    Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
    Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single peptides and combination modalities for triple negative breast cancer.
    Razazan A; Behravan J
    J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
    Xie X; Lee J; Iwase T; Kai M; Ueno NT
    Expert Opin Ther Targets; 2022 May; 26(5):405-425. PubMed ID: 35574694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in targeted strategies for triple-negative breast cancer.
    Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
    Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
    Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer.
    Naik A; Monjazeb AM; Decock J
    Front Immunol; 2019; 10():1940. PubMed ID: 31475003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
    Michaels E; Chen N; Nanda R
    Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.